 |
|
|
|
|
|
|
|
 |
Results for 'Asthma Therapeutics' |
|
|
| Title |
 |
Publication Date |
|
Price |
|
Relevance |
 |
|
|
|
|
Enzyme Inhibitors with Broad Therapeutic Applications
|
June 2006 |
£3255 |
35.5 % |
Chronotherapeutics
|
September 2003 |
£75 |
35 % |
Premium Company Profile - Tanox
|
January 2008 |
£265 |
29 % |
Launching Combination Products
Brand Extension and Franchise Development Strategies
|
January 2008 |
£1995 |
29 % |
Altana Pharmaceutical Company Intelligence Report
|
August 2006 |
£795 |
28.5 % |
The Asthma and COPD Market Outlook
Market analysis of future growth and leading players by sector
|
January 2005 |
£1495 |
26.6 % |
Respironics Medical Device Company Intelligence Report
Medical Devices, Company Profile and Healthcare
|
November 2005 |
£295 |
26 % |
Pharmacogenomics: The Search for Individualized Therapies
|
April 2002 |
£65 |
24.85 % |
World Asthma and COPD Treatment Market, 2006-2011, The
A Changing Market with Increasing Potential
|
September 2006 |
£1499 |
24.15 % |
Tanox, Inc. - SWOT Analysis
|
November 2007 |
£66 |
24 % |
Stakeholder Insight: Asthma
Combination Therapy Appropriate for Everyone?
|
January 2005 |
£8000 |
23.1 % |
Drug Delivery Markets, Vol. IV: Transdermal
|
April 2007 |
£1675 |
22.75 % |
Drug Delivery Markets, Vol III
Pulmonary Delivery Systems
|
March 2007 |
£1675 |
22.75 % |
Inflammatory Disease Therapeutics
Pipelines and Competitive Dynamics
|
June 2005 |
£2140 |
21.7 % |
Boehringer Ingelheim Gmbh
Pharmavitae Profile
|
December 2007 |
£3010 |
18.55 % |
Valuing and Structuring Pharmaceutical Licensing Agreements
|
February 2003 |
£895 |
17.85 % |
Alexion Pharmaceuticals Inc: Premium Company Profile
|
February 2008 |
£265 |
17.5 % |
Merck & Co Pharmaceutical Company Intelligence Report
Pipeline Products Performance Potential
|
October 2007 |
£595 |
17 % |
Disease Management
|
January 2004 |
£29.95 |
16.8 % |
New Drug Futures: Respiratory Chapter
|
May 2006 |
£695 |
16.1 % |
Stakeholder Insight
Asthma - over-Prescribing Is Common in Intermittent and Mild Forms of Asthma
|
July 2008 |
£7600 |
15.75 % |
Outlook for RNAi, 2007
siRNA and miRNA in biology, diagnostics and therapeutics
|
June 2007 |
£1495 |
15.75 % |
Drug Delivery Series I-IV
|
April 2007 |
£4790 |
15.05 % |
Immunomodulators
Therapeutic Needs, Pipelines & Prospects
|
August 2007 |
£1495 |
15.05 % |
Top Companies and Products in the RNA/DNA Therapy Products Market Forecasts:
The Challenge Of Turning Technology Into Therapy
|
July 2007 |
£1999 |
14.7 % |
Vaccines Market Insight
Products, Pipelines & Market Outlook
|
January 2007 |
£1095 |
14.35 % |
The Outlook For RNAi
Accelerating drug discovery and the development of RNAi therapeutics
|
January 2005 |
£1495 |
13.65 % |
Biotech in Autoimmune and Inflammatory Disease 2006
2nd Edition
|
May 2006 |
£2010 |
13.65 % |
Therapeutics for Inflammatory Diseases
Current Challenges and Future Market
|
March 2006 |
£3255 |
13.65 % |
Innovation in Drug Delivery
The future of nanotechnology and non-invasive protein delivery
|
November 2006 |
£1495 |
13.65 % |
Cannabinoids
A Potential Blockbuster
|
February 2005 |
£1499 |
12.6 % |
Dynamic Antibody Industry
|
August 2005 |
£3045 |
11.9 % |
Monoclonal Antibody Therapies 2004
Entering A New Competitive Era
|
May 2004 |
£1510 |
11.55 % |
Monoclonal Antibodies 2007
Competitive Landscape & Pipeline Insight
|
January 2007 |
£1510 |
11.2 % |
Eu Paediatric Medicines Regulation
Boon or Burden?
|
January 2007 |
£1095 |
11 % |
Global Protein Therapeutics Market, The
Market Dynamics and Pipeline Analysis
|
December 2006 |
£2010 |
10.85 % |
Rimonabant: The first of the Cannabinoid blockbusters
|
June 2007 |
£1499 |
10.85 % |
Nitric Oxide
Therapeutics, Markets and Companies
|
September 2008 |
£1005 |
10.5 % |
Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
|
June 2008 |
£2025 |
10.5 % |
Scrip R&D Databook 2006
|
January 2006 |
£1295 |
10.15 % |
Obesity Drug Markets in the US and EU
Analysis of product pipelines and the competitive environment
|
July 2008 |
£1995 |
10 % |
Transdermal Drug Delivery
Technologies, Markets, and Companies
|
September 2008 |
£1675 |
9.8 % |
The Indian Pharmaceutical Market Analysis and Forecasts 2008-2023
|
May 2008 |
£1499 |
9.8 % |
Pharmacogenomics: New Technologies
In the Development of Personalized Therapies
|
August 2005 |
£3045 |
9.45 % |
RNAi
Technologies, Markets and Companies
|
September 2008 |
£2010 |
9.1 % |
The Future of Systems Biology
Emerging technologies and their impact on drug discovery, development and diagnostics
|
January 2005 |
£1495 |
8.4 % |
Pharmacoeconomics & Success in the Marketplace
|
January 2005 |
£1499 |
7.7 % |
Personalized Medicine
scientific & commercial aspects
|
September 2008 |
£2680 |
7.35 % |
Indian Pharmaceutical Market, 2006-2011
|
June 2006 |
£1499 |
7 % |
Preparing Health Technology Submissions for Pharmaceutical Products
Meeting Formulary Submission Requirements for New Product Assessments and Disease Area & Therapeutic Class Reviews
|
April 2006 |
£1550 |
7 % |
Global Generics Guide: Part 2
Benchmarking country markets and strategic issue
|
June 2006 |
£8695 |
6.65 % |
Combination Therapies
Benefits and Challenges in Drug, Device, and Biologicals Development
|
October 2005 |
£1945 |
5.6 % |
Parexel's Pharmaceutical R&D Statistical Sourcebook 2007/2008
|
May 2007 |
£285 |
4.9 % |
PAREXEL's Bio/Pharma R&D Statistical Sourcebook 2008/2009
|
June 2008 |
£285 |
4.55 % |
Invacare Medical Device Company Intelligence Report
|
July 2005 |
£295 |
2.8 % |
|
|
|
|
